Skip to main content
Premium Trial:

Request an Annual Quote

Millipore Acquires Epitome's EpiTag Technology

NEW YORK (GenomeWeb News) – Millipore has acquired the assets associated with Epitome Biosystems' EpiTag technology for an undisclosed sum, the Billerica, Mass.-based firm said today.

The acquisition provides Millipore with a bioinformatics-driven technology for developing antibodies. The firm intends to use the EpiTag technology to develop a range of new multiplex immunoassay kits that can be used with the Luminex xMAP platform, to which Millipore holds a license. The kits will enable researchers to "more efficiently measure, detect, and analyze proteins and cell signaling pathways," said Millipore.

"The EpiTag technology will allow us to develop multiplex immunoassays for cellular targets that were previously very difficult to detect and quantify," Rick Ryan, VP of Millipore's drug discovery business unit, said in a statement.

Millipore currently sells Milliplex MAP assays that run on the Luminex platform for research in the immunology, inflammation, and metabolic disease areas.

The Scan

Alzheimer's Risk Gene Among Women

CNN reports that researchers have found that variants in MGMT contribute to Alzheimer's disease risk among women but not men.

Still Hanging Around

The Guardian writes that persistent pockets of SARS-CoV-2 in the body could contribute to long COVID.

Through a Little Spit

Enteric viruses like norovirus may also be transmitted through saliva, not just the fecal-oral route, according to New Scientist.

Nature Papers Present Method to Detect Full Transcriptome, Viruses Infecting Asgard Archaea, More

In Nature this week: VASA-seq approach to detect full transcriptome, analysis of viruses infecting Asgard archaea, and more.